Alnylam Pharmaceuticals (ALNY) stands as the established leader in RNAi therapeutics, a class of medicines that silence disease-causing genes upstream of traditional protein-targeting drugs. With several commercialized therapies and a delivery platform that translates predictably across liver-targeted diseases, the company holds a durable technological moat that is difficult for competitors to replicate.
Its medium-term positioning centers on the TTR franchise, anchored by Amvuttra, and on “Alnylam 2030,” a five-year strategy unveiled in early 2026 that targets leadership in the global TTR market, a 25%-plus total revenue compound annual growth rate through 2030, and roughly a 30% non-GAAP operating margin. The plan also calls for expanding delivery to 10 tissue types and more than 40 clinical programs, signaling an ambition to move from rare diseases into larger, mainstream indications such as hypertension, Alzheimer’s disease, and metabolic disorders. This breadth, combined with a largely wholly owned pipeline, supports a structurally differentiated growth profile, though execution risk and competitive pricing pressure remain the principal structural challenges.
Several developments could shape investor sentiment in the coming quarters. The most important is nucresiran’s Phase 3 program: readouts from the TRITON-CM and TRITON-PN trials will test whether the next-generation therapy can deliver a best-in-class profile in ATTR cardiomyopathy and polyneuropathy, supporting planned launches in the late 2020s. Meanwhile, zilebesiran’s ZENITH cardiovascular outcomes trial, run with Roche, represents Alnylam’s bid to enter the vast hypertension market with a quarterly-dosed therapy.
Earlier-stage readouts also matter: mivelsiran’s Alzheimer’s and cerebral amyloid angiopathy (CAA) trials, plus Phase 1 data for ALN-6400 (bleeding disorders), ALN-4324 (type 2 diabetes), and ALN-HTT02 (Huntington’s disease), could broaden the narrative beyond TTR. On the commercial side, quarterly Amvuttra demand data will be closely watched after management moderated full-year revenue guidance in 2026, citing normalization of initial pent-up demand. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Analyst sentiment is broadly positive but increasingly balanced. Most covering analysts maintain Buy or Strong Buy ratings, yet several firms lowered price targets during 2026. For example, UBS trimmed its target while keeping a Buy, citing moderating near-term growth but supporting catalysts, while H.C. Wainwright raised its target on pipeline confidence. The average one-year price target has hovered in the mid-$400s, above the recent share price, reflecting constructive but cautious expectations.
As a high-growth biotechnology company, Alnylam is sensitive to interest rates: higher long-term yields tend to compress the valuation of companies whose cash flows are weighted far into the future. Inflation and healthcare cost pressures also feed into drug-pricing debates, and U.S. policies such as the Inflation Reduction Act’s Medicare negotiation provisions create a longer-term reimbursement overhang for high-priced specialty therapies.
Conversely, favorable structural forces support the outlook. An aging population is expanding the addressable market for ATTR cardiomyopathy and related cardiovascular diseases, while growing clinical acceptance of RNAi as a modality lowers adoption barriers. Competitive dynamics have also tilted in Alnylam’s favor, with Pfizer’s competing franchise insulated from generics until mid-2031 and a key rival trial failing in 2026. These forces connect directly to the company’s core commercial and pipeline strategy.
Looking into 2026 and beyond, Alnylam’s trajectory hinges on executing the “Alnylam 2030” framework. Near term, the priority is demonstrating that Amvuttra demand growth can reaccelerate in ATTR cardiomyopathy after an expected post-launch normalization, while advancing nucresiran toward what management frames as best-in-class launches in polyneuropathy by 2028 and cardiomyopathy by 2030. Success here would extend the TTR franchise’s durability well past the current decade.
Longer term, the company’s expansion into hypertension, Alzheimer’s disease, and metabolic conditions represents the largest untapped opportunity but also carries the highest clinical and commercial risk. Sustaining margins while investing roughly 30% of revenue in research and development will test capital-allocation discipline, even as collaborations with Roche and Regeneron offset some costs. Competitive threats from large-cap peers and alternative modalities, plus evolving regulatory and pricing frameworks, remain the key variables that could reshape consensus expectations. Analysts’ long-term assumptions generally reflect confidence in pipeline breadth, but the wide range of published price targets underscores the genuine uncertainty embedded in the outlook.
In my own research process, I often turn to Tickeron’s Trend Prediction Engine to add a quantitative layer when evaluating names like ALNY. The tool provides AI-driven forecasts on whether a stock may trend bullish, bearish, or sideways over the coming week or month, helping identify developing trends, potential breakouts, and reversals with historical context and alert functionality. It serves as a useful complement to fundamental analysis for timing decisions in volatile sectors such as biotechnology.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
On November 13, 2026, the Stochastic Oscillator for ALNY moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 65 instances where the indicator left the oversold zone. In 50 of the 65 cases the stock moved higher in the following days. This puts the odds of a move higher at over 77%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Indicator exited the oversold zone, 16 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on ALNY as a result. In 57 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
Following a +1.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 216 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 33 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for ALNY entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.409) is normal, around the industry mean (3.586). P/E Ratio (26.566) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of therapeutics based on RNA interference
Industry Biotechnology